AERG


Janney Capital Maintains Buy On Aegerion Ahead Of 2Q14 Earnings Report

In a research report released today, Janney Capital analyst Kimberly Lee maintained a Buy rating on Aegerion Pharmaceuticals (AEGR) with a $90 price target, which …